ALS Patients Ask FDA To See Risk Their Way
Executive Summary
An FDA panel got an earful on the review and regulation of drugs for amyotrophic lateral sclerosis Feb. 25 during a public hearing convened under the agency’s plan to involve patient networks in the regulatory process, particularly where it concerns lowering barriers to drug development for ALS.
You may also be interested in...
BrainStorm’s Phase III Data Do Not Support Clinical Benefit Of NurOwn In ALS, US FDA Says
Agency’s unusual public statement about an investigational product's development status may be aimed at countering bullish comments from the sponsor; FDA cites failure of pivotal trial on the primary and secondary endpoints and ‘modest excess in deaths’ with the cell therapy.
FDA Asks Genervon To Release ALS Drug Trial Data As Pressure From Patients Builds
In response to calls from patients and others about GM604, FDA issued a public statement calling on the company to release full clinical trial data for its investigative amyotrophic lateral sclerosis drug, which recently completed a Phase IIa trial.
Scientific Advances Increase Potential For Drugs To Treat ALS
New understanding of the spectrum of CNS disorders and rising interest from biotechs have revealed new targets, new biomarkers and new opportunities to treat the fast-acting and deadly neurodegenerative disease. Add to that an open stakeholder forum hosted by FDA Feb. 25 that could clarify regulatory and clinical expectations, and the tide may be turning on amyotrophic lateral sclerosis.